4-phenylbutyric acid has been researched along with tamoxifen in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chung, YL; Lin, CH; Sheu, ML; Yang, SC; Yen, SH | 1 |
1 review(s) available for 4-phenylbutyric acid and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for 4-phenylbutyric acid and tamoxifen
| Article | Year |
|---|---|
Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 3; Caspases; Cell Membrane; Cell Nucleus; Cell Separation; Cytosol; DNA Fragmentation; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunohistochemistry; Microscopy, Confocal; Microscopy, Fluorescence; Mitochondria; Phenylbutyrates; Precipitin Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Retinoic Acid; Subcellular Fractions; Tamoxifen; Time Factors; Tretinoin; Tumor Cells, Cultured | 2002 |